IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) will provide a clinical data update on December 7, 2021, focusing on the ongoing Phase 1/2 trial of darovasertib and crizotinib for metastatic uveal melanoma. The company plans a pre-market press release and will host a conference call at 8:30 a.m. ET. Key discussion points include clinical efficacy data, potential registration-enabling trial designs, and target patient population analysis. This event aims to showcase clinical benchmarks and potential expansion into other cancer types.

Positive

• Upcoming clinical data update on December 7, 2021, provides insights into darovasertib and crizotinib combination efficacy.
• Conference will cover potential registration-enabling trials, enhancing future business prospects.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its plans for a clinical data update on December 7, 2021, including plans to issue a pre-market press release and host a conference call and webcast to discuss clinical data from the ongoing Phase 1/2 trial evaluating darovasertib and crizotinib combination in patients with metastatic uveal melanoma (MUM) (ClinicalTrials.gov Identifier: NCT03947385).

IDEAYA will host a conference call and webcast at 8:30 a.m. ET on Tuesday, December 7, 2021, with the following agenda topics:

• Clinical landscape in Metastatic Uveal Melanoma, including clinical efficacy benchmarks
• Mechanistic rationale, preclinical data, and clinical translational data supporting the darovasertib (PKC) and crizotinib (cMET) synthetic lethal combination
• Darovasertib and crizotinib Phase 1/2 clinical combination data, with a summary of clinical efficacy, including partial responses, and adverse events
• Potential registration-enabling clinical trial designs for darovasertib and crizotinib combination
• Darovasertib target patient population analysis in Metastatic Uveal Melanoma, Adjuvant Uveal Melanoma, and GNAQ/GNA11-mutant Skin Melanomas; potential expansion opportunities are being evaluated, including MET amplified cancers and hepatocellular carcinoma

The link to the webcast and dial-in instructions for the conference call will be available through the Investor Relations Events section of the Company's website at: https://ir.ideayabio.com/events.  An archived replay will be accessible for 90 days following the event.

About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the darovasertib and crizotinib combination clinical data press release and webcast, including agenda topics.  Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, the effects on IDEAYA's business of the worldwide COVID-19 pandemic, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10Q filed on November 15, 2021 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.  

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-investor-webcast-to-review-clinical-data-from-phase-12-trial-of-darovasertib-combination-with-crizotinib-in-metastatic-uveal-melanoma-301432493.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What is the purpose of the December 7, 2021 conference call regarding IDYA?

The conference call is set to discuss clinical data from the Phase 1/2 trial of the darovasertib and crizotinib combination for metastatic uveal melanoma.

What will be covered in the clinical data update for IDYA on December 7, 2021?

The update will cover clinical efficacy benchmarks, combination data, and potential trial designs for registration.

What are the next steps for IDYA following the clinical data update?

Next steps may involve evaluating registration-enabling trial designs and potential expansion into other cancer types based on clinical data.

What does the Phase 1/2 trial for IDYA involve?

The trial involves evaluating the combination of darovasertib and crizotinib in patients with metastatic uveal melanoma.